KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Tax Provisions (2019 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Tax Provisions for 10 consecutive years, with -$25.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Tax Provisions rose 77.05% year-over-year to -$25.3 million, compared with a TTM value of $9.4 million through Dec 2025, up 109.47%, and an annual FY2025 reading of $9.4 million, up 109.47% over the prior year.
  • Tax Provisions was -$25.3 million for Q4 2025 at Alnylam Pharmaceuticals, down from -$12.1 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $30.9 million in Q2 2025 and bottomed at -$110.2 million in Q4 2024.
  • Average Tax Provisions over 5 years is -$3.9 million, with a median of $1.1 million recorded in 2021.
  • The sharpest move saw Tax Provisions skyrocketed 13091.3% in 2023, then tumbled 60315.85% in 2024.
  • Year by year, Tax Provisions stood at -$1.8 million in 2021, then surged by 125.62% to $472000.0 in 2022, then crashed by 61.23% to $183000.0 in 2023, then crashed by 60315.85% to -$110.2 million in 2024, then soared by 77.05% to -$25.3 million in 2025.
  • Business Quant data shows Tax Provisions for ALNY at -$25.3 million in Q4 2025, -$12.1 million in Q3 2025, and $30.9 million in Q2 2025.